Addolorato G, Leggio L, Agabio R, Colombo G, Gasbarrini G
Institute of Internal Medicine, Catholic University of Rome, Rome, Italy.
Int J Clin Pract. 2006 Aug;60(8):1003-8. doi: 10.1111/j.1742-1241.2006.01065.x.
Recent preclinical and clinical studies have suggested that baclofen, the prototypic gamma-aminobutyric acid B (GABA(B)) receptor agonist, is a promising pharmacological compound for use in the treatment of alcohol dependence. In particular, baclofen has been found to suppress symptoms of alcohol withdrawal syndrome with an efficacy comparable with that of the 'gold standard' diazepam. Moreover, baclofen has proven effective in the prevention of relapse due to its ability to reduce alcohol intake and craving in alcoholic patients. Baclofen proved to be manageable, producing no significant side effects and displaying no addictive properties. The efficacy of the drug in the management of both alcohol withdrawal syndrome and relapse prevention should entail a vastly simplified pharmacotherapy of alcohol dependence.
近期的临床前和临床研究表明，原型γ-氨基丁酸B（GABA(B)）受体激动剂巴氯芬是一种用于治疗酒精依赖的有前景的药物化合物。特别是，已发现巴氯芬可抑制酒精戒断综合征的症状，其疗效与“金标准”地西泮相当。此外，由于巴氯芬能够减少酒精性患者的酒精摄入量和渴望感，已证明其在预防复发方面有效。事实证明，巴氯芬易于管理，不会产生明显的副作用，也不具有成瘾性。该药物在治疗酒精戒断综合征和预防复发方面的疗效应会使酒精依赖的药物治疗大大简化。
